Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release
Launched by DARTMOUTH-HITCHCOCK MEDICAL CENTER · Mar 19, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how targeted radiation therapy can help prevent Dupuytren's Contracture from coming back after non-surgical treatment with an injection called Collagenase Clostridium Histolyticum (CCH). Dupuytren's Contracture is a condition that causes the fingers to bend towards the palm, making it difficult to fully extend them. The trial will involve participants who are 45 years or older, have a noticeable bending of their fingers, and cannot lay their hand flat on a table.
Participants in the trial will first receive the CCH injection to release the contracture, followed by five days of daily radiation therapy. After a break of 6 to 8 weeks, they will receive another five days of radiation therapy. The study is currently looking for participants, and it's important to note that those with certain health issues or who are pregnant cannot take part. This trial aims to provide valuable information on whether radiation therapy can reduce the chances of Dupuytren's Contracture returning after treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 45 or greater with DC
- • Extension deficit \>10 degrees
- • Unable to simultaneously place the affected finger and palm flat on a table.
- • Women included in the study will be post-menopausal or using contraception, and a pregnancy test will be performed as standard of care.
- • For patients who are having multiple CCH injections, only the first 2 joints on given hand will be included
- Exclusion Criteria:
- • Unsuccessful non-surgical release (\> N/1 disease)
- • They develop an open wound during CCH
- • Breast feeding or pregnancy
- • A chronic muscular, neurologic, or neuromuscular disorder affecting the hands.
- • Less than the age of 45
- • They have previously undergone radiation on the hand in which they plan to get CCH injections
- • They are pregnant women, impaired adults or prisoners
About Dartmouth Hitchcock Medical Center
Dartmouth-Hitchcock Medical Center (DHMC) is a leading academic medical institution located in Lebanon, New Hampshire, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a major teaching hospital affiliated with the Geisel School of Medicine at Dartmouth, DHMC integrates cutting-edge clinical trials and translational research into its comprehensive patient care approach. The center emphasizes collaboration across disciplines, aiming to enhance patient outcomes through rigorous scientific investigation, education, and community engagement. With a focus on ethical practices and patient safety, DHMC is dedicated to contributing to the advancement of medical knowledge and improving health care delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lebanon, New Hampshire, United States
Patients applied
Trial Officials
Lance Warhold, MD
Principal Investigator
Dartmouth Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported